Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine

Identifieur interne : 000508 ( PascalFrancis/Curation ); précédent : 000507; suivant : 000509

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine

Auteurs : YUXIAN HE [États-Unis] ; JINGJING LI [États-Unis] ; LANYING DU [République populaire de Chine] ; XUXIA YAN [États-Unis] ; GUANEAN HU [République populaire de Chine] ; YUSEN ZHOU [République populaire de Chine] ; SHIBO JIANG [États-Unis]

Source :

RBID : Pascal:06-0337481

Descripteurs français

English descriptors

Abstract

The spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is considered as a major antigen for vaccine design. We previously demonstrated that the receptor-binding domain (RBD: residues 318-510) of S protein contains multiple conformation-dependent neutralizing epitopes (Conf I to VI) and serves as a major target of SARS-CoV neutralization. Here, we further characterized the antigenic structure in the RBD by a panel of novel mAbs isolated from the mice immunized with an inactivated SARS-CoV vaccine. Ten of the RBD-specific mAbs were mapped to four distinct groups of conformational epitopes (designated Group A to D), and all of which had potent neutralizing activity against S protein-pseudotyped SARS viruses. Group A, B, C mAbs target the epitopes that may overlap with the previously characterized Conf I, III, and VI respectively, but they display different capacity to block the receptor binding. Group D mAb (S25) was directed against a unique epitope by its competitive binding. Two anti-RBD mAbs recognizing the linear epitopes (Group E) were mapped to the RBD residues 335-352 and 442-458, respectively, and none of them inhibited the receptor binding and virus entry. Surprisingly, most neutralizing epitopes (Groups A to C) could be completely disrupted by single amino acid substitutions (e.g., D429A, R441A or D454A) or by deletions of several amino acids at the N-terminal or C-terminal region of the RBD; however, the Group D epitope was not sensitive to the mutations, highlighting its importance for vaccine development. These data provide important information for understanding the antigenicity and immunogenicity of SARS-CoV, and this panel of novel mAbs can be used as tools for studying the structure of S protein and for guiding SARS vaccine design.
pA  
A01 01  1    @0 0264-410X
A02 01      @0 VACCDE
A03   1    @0 Vaccine
A05       @2 24
A06       @2 26
A08 01  1  ENG  @1 Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
A11 01  1    @1 YUXIAN HE
A11 02  1    @1 JINGJING LI
A11 03  1    @1 LANYING DU
A11 04  1    @1 XUXIA YAN
A11 05  1    @1 GUANEAN HU
A11 06  1    @1 YUSEN ZHOU
A11 07  1    @1 SHIBO JIANG
A14 01      @1 Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street @2 New York, NY 10021 @3 USA @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 7 aut.
A14 02      @1 Beijing Institute of Microbiology and Epidemiology @2 Beijing 100071 @3 CHN @Z 3 aut. @Z 5 aut. @Z 6 aut.
A20       @1 5498-5508
A21       @1 2006
A23 01      @0 ENG
A43 01      @1 INIST @2 20289 @5 354000142473330140
A44       @0 0000 @1 © 2006 INIST-CNRS. All rights reserved.
A45       @0 42 ref.
A47 01  1    @0 06-0337481
A60       @1 P
A61       @0 A
A64 01  1    @0 Vaccine
A66 01      @0 GBR
C01 01    ENG  @0 The spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is considered as a major antigen for vaccine design. We previously demonstrated that the receptor-binding domain (RBD: residues 318-510) of S protein contains multiple conformation-dependent neutralizing epitopes (Conf I to VI) and serves as a major target of SARS-CoV neutralization. Here, we further characterized the antigenic structure in the RBD by a panel of novel mAbs isolated from the mice immunized with an inactivated SARS-CoV vaccine. Ten of the RBD-specific mAbs were mapped to four distinct groups of conformational epitopes (designated Group A to D), and all of which had potent neutralizing activity against S protein-pseudotyped SARS viruses. Group A, B, C mAbs target the epitopes that may overlap with the previously characterized Conf I, III, and VI respectively, but they display different capacity to block the receptor binding. Group D mAb (S25) was directed against a unique epitope by its competitive binding. Two anti-RBD mAbs recognizing the linear epitopes (Group E) were mapped to the RBD residues 335-352 and 442-458, respectively, and none of them inhibited the receptor binding and virus entry. Surprisingly, most neutralizing epitopes (Groups A to C) could be completely disrupted by single amino acid substitutions (e.g., D429A, R441A or D454A) or by deletions of several amino acids at the N-terminal or C-terminal region of the RBD; however, the Group D epitope was not sensitive to the mutations, highlighting its importance for vaccine development. These data provide important information for understanding the antigenicity and immunogenicity of SARS-CoV, and this panel of novel mAbs can be used as tools for studying the structure of S protein and for guiding SARS vaccine design.
C02 01  X    @0 002A05F04
C03 01  X  FRE  @0 Identification @5 05
C03 01  X  ENG  @0 Identification @5 05
C03 01  X  SPA  @0 Identificación @5 05
C03 02  X  FRE  @0 Déterminant antigénique @5 06
C03 02  X  ENG  @0 Antigenic determinant @5 06
C03 02  X  SPA  @0 Determinante antigénico @5 06
C03 03  X  FRE  @0 Protéine @5 07
C03 03  X  ENG  @0 Protein @5 07
C03 03  X  SPA  @0 Proteína @5 07
C03 04  X  FRE  @0 Vaccin @5 08
C03 04  X  ENG  @0 Vaccine @5 08
C03 04  X  SPA  @0 Vacuna @5 08
C03 05  X  FRE  @0 Anticorps neutralisant @5 09
C03 05  X  ENG  @0 Neutralizing antibody @5 09
C03 05  X  SPA  @0 anticuerpo neutralizante @5 09
C03 06  X  FRE  @0 Syndrome respiratoire aigu sévère @2 NM @5 14
C03 06  X  ENG  @0 Severe acute respiratory syndrome @2 NM @5 14
C03 06  X  SPA  @0 Síndrome respiratorio agudo severo @2 NM @5 14
C07 01  X  FRE  @0 Appareil respiratoire pathologie @5 13
C07 01  X  ENG  @0 Respiratory disease @5 13
C07 01  X  SPA  @0 Aparato respiratorio patología @5 13
C07 02  X  FRE  @0 Virose
C07 02  X  ENG  @0 Viral disease
C07 02  X  SPA  @0 Virosis
C07 03  X  FRE  @0 Infection
C07 03  X  ENG  @0 Infection
C07 03  X  SPA  @0 Infección
C07 04  X  FRE  @0 Poumon pathologie @5 16
C07 04  X  ENG  @0 Lung disease @5 16
C07 04  X  SPA  @0 Pulmón patología @5 16
N21       @1 219
N44 01      @1 OTO
N82       @1 OTO

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:06-0337481

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine</title>
<author>
<name sortKey="Yuxian He" sort="Yuxian He" uniqKey="Yuxian He" last="Yuxian He">YUXIAN HE</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Jingjing Li" sort="Jingjing Li" uniqKey="Jingjing Li" last="Jingjing Li">JINGJING LI</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Lanying Du" sort="Lanying Du" uniqKey="Lanying Du" last="Lanying Du">LANYING DU</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author>
<name sortKey="Xuxia Yan" sort="Xuxia Yan" uniqKey="Xuxia Yan" last="Xuxia Yan">XUXIA YAN</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Guanean Hu" sort="Guanean Hu" uniqKey="Guanean Hu" last="Guanean Hu">GUANEAN HU</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author>
<name sortKey="Yusen Zhou" sort="Yusen Zhou" uniqKey="Yusen Zhou" last="Yusen Zhou">YUSEN ZHOU</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author>
<name sortKey="Shibo Jiang" sort="Shibo Jiang" uniqKey="Shibo Jiang" last="Shibo Jiang">SHIBO JIANG</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">06-0337481</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0337481 INIST</idno>
<idno type="RBID">Pascal:06-0337481</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000482</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000508</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine</title>
<author>
<name sortKey="Yuxian He" sort="Yuxian He" uniqKey="Yuxian He" last="Yuxian He">YUXIAN HE</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Jingjing Li" sort="Jingjing Li" uniqKey="Jingjing Li" last="Jingjing Li">JINGJING LI</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Lanying Du" sort="Lanying Du" uniqKey="Lanying Du" last="Lanying Du">LANYING DU</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author>
<name sortKey="Xuxia Yan" sort="Xuxia Yan" uniqKey="Xuxia Yan" last="Xuxia Yan">XUXIA YAN</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Guanean Hu" sort="Guanean Hu" uniqKey="Guanean Hu" last="Guanean Hu">GUANEAN HU</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author>
<name sortKey="Yusen Zhou" sort="Yusen Zhou" uniqKey="Yusen Zhou" last="Yusen Zhou">YUSEN ZHOU</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author>
<name sortKey="Shibo Jiang" sort="Shibo Jiang" uniqKey="Shibo Jiang" last="Shibo Jiang">SHIBO JIANG</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint>
<date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antigenic determinant</term>
<term>Identification</term>
<term>Neutralizing antibody</term>
<term>Protein</term>
<term>Severe acute respiratory syndrome</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Identification</term>
<term>Déterminant antigénique</term>
<term>Protéine</term>
<term>Vaccin</term>
<term>Anticorps neutralisant</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is considered as a major antigen for vaccine design. We previously demonstrated that the receptor-binding domain (RBD: residues 318-510) of S protein contains multiple conformation-dependent neutralizing epitopes (Conf I to VI) and serves as a major target of SARS-CoV neutralization. Here, we further characterized the antigenic structure in the RBD by a panel of novel mAbs isolated from the mice immunized with an inactivated SARS-CoV vaccine. Ten of the RBD-specific mAbs were mapped to four distinct groups of conformational epitopes (designated Group A to D), and all of which had potent neutralizing activity against S protein-pseudotyped SARS viruses. Group A, B, C mAbs target the epitopes that may overlap with the previously characterized Conf I, III, and VI respectively, but they display different capacity to block the receptor binding. Group D mAb (S25) was directed against a unique epitope by its competitive binding. Two anti-RBD mAbs recognizing the linear epitopes (Group E) were mapped to the RBD residues 335-352 and 442-458, respectively, and none of them inhibited the receptor binding and virus entry. Surprisingly, most neutralizing epitopes (Groups A to C) could be completely disrupted by single amino acid substitutions (e.g., D429A, R441A or D454A) or by deletions of several amino acids at the N-terminal or C-terminal region of the RBD; however, the Group D epitope was not sensitive to the mutations, highlighting its importance for vaccine development. These data provide important information for understanding the antigenicity and immunogenicity of SARS-CoV, and this panel of novel mAbs can be used as tools for studying the structure of S protein and for guiding SARS vaccine design.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0264-410X</s0>
</fA01>
<fA02 i1="01">
<s0>VACCDE</s0>
</fA02>
<fA03 i2="1">
<s0>Vaccine</s0>
</fA03>
<fA05>
<s2>24</s2>
</fA05>
<fA06>
<s2>26</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>YUXIAN HE</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>JINGJING LI</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>LANYING DU</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>XUXIA YAN</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>GUANEAN HU</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>YUSEN ZHOU</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>SHIBO JIANG</s1>
</fA11>
<fA14 i1="01">
<s1>Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street</s1>
<s2>New York, NY 10021</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Beijing Institute of Microbiology and Epidemiology</s1>
<s2>Beijing 100071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20>
<s1>5498-5508</s1>
</fA20>
<fA21>
<s1>2006</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20289</s2>
<s5>354000142473330140</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>42 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>06-0337481</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Vaccine</s0>
</fA64>
<fA66 i1="01">
<s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>The spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is considered as a major antigen for vaccine design. We previously demonstrated that the receptor-binding domain (RBD: residues 318-510) of S protein contains multiple conformation-dependent neutralizing epitopes (Conf I to VI) and serves as a major target of SARS-CoV neutralization. Here, we further characterized the antigenic structure in the RBD by a panel of novel mAbs isolated from the mice immunized with an inactivated SARS-CoV vaccine. Ten of the RBD-specific mAbs were mapped to four distinct groups of conformational epitopes (designated Group A to D), and all of which had potent neutralizing activity against S protein-pseudotyped SARS viruses. Group A, B, C mAbs target the epitopes that may overlap with the previously characterized Conf I, III, and VI respectively, but they display different capacity to block the receptor binding. Group D mAb (S25) was directed against a unique epitope by its competitive binding. Two anti-RBD mAbs recognizing the linear epitopes (Group E) were mapped to the RBD residues 335-352 and 442-458, respectively, and none of them inhibited the receptor binding and virus entry. Surprisingly, most neutralizing epitopes (Groups A to C) could be completely disrupted by single amino acid substitutions (e.g., D429A, R441A or D454A) or by deletions of several amino acids at the N-terminal or C-terminal region of the RBD; however, the Group D epitope was not sensitive to the mutations, highlighting its importance for vaccine development. These data provide important information for understanding the antigenicity and immunogenicity of SARS-CoV, and this panel of novel mAbs can be used as tools for studying the structure of S protein and for guiding SARS vaccine design.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002A05F04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Identification</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Identification</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Identificación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Déterminant antigénique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Antigenic determinant</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Determinante antigénico</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Protéine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Protein</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Proteína</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Vaccin</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Vaccine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Vacuna</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Anticorps neutralisant</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Neutralizing antibody</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>anticuerpo neutralizante</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Appareil respiratoire pathologie</s0>
<s5>13</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Respiratory disease</s0>
<s5>13</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Aparato respiratorio patología</s0>
<s5>13</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Virose</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Viral disease</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Virosis</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Infección</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Poumon pathologie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Lung disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Pulmón patología</s0>
<s5>16</s5>
</fC07>
<fN21>
<s1>219</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000508 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000508 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0337481
   |texte=   Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein : Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021